Product Pathways - Apoptosis
TRAIL (C92B9) Rabbit mAb (PE Conjugate) #37020
|37020S||100 µl ( 50 tests )||￥4,060.00 现货查询||购买询价|
|37020||carrier free & custom formulation / quantity||email request|
Species cross-reactivity is determined by western blot.
Applications Key: F=Flow Cytometry,
Specificity / Sensitivity
TRAIL (C92B9) Rabbit mAb (PE Conjugate) detects endogenous levels of total human TRAIL protein.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys60 of human TRAIL, within the extracellular region of the protein.
This Cell Signaling Technology antibody is conjugated to phycoerythrin (PE) and tested in-house for direct flow cytometry analysis in human cells. This antibody is expected to exhibit the same species cross-reactivity as the unconjugated TRAIL (C92B9) Rabbit mAb #3219.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also referred to as Apo2 ligand, first identified based on its sequence homology to TNF and Fas/Apo ligand is a member of the TNF family of cytokines and either exists as a type II membrane or soluble protein (1,2). TRAIL induces apoptosis in a variety of transformed cell lines and plays a role in anti-tumor and anti-viral immune surveillance (3). TRAIL signals via binding with death receptors DR4 (TRAIL-R1) (4) and DR5 (TRAIL-R2) (5-8) which can trigger apoptosis as well as NF-κB activation (7,9). Death domains on these receptors leads to the recruitment of a death-induced signaling complex (DISC) leading to caspase-8 and subsequent caspase-3 activation. In addition, TRAIL binds with decoy receptors DcR1 (TRAIL-R3) (10-13) and DcR2 (TRAIL-R4, TRUNDD) (14-15) which lack the functional cytoplasmic death domain antagonizing TRAIL-induced apoptosis. Osteoprotegerin (OPG) has also been identified as receptor capable of inhibiting TRAIL-induced apoptosis (16). The selectivity of soluble TRAIL at triggering apoptosis in transformed cells as compared to normal cells has led to its investigation as a potential cancer therapeutic (17-18).
- Wiley, S.R. et al. (1995) Immunity 3, 673-82.
- Pitti, R.M. et al. (1996) J Biol Chem 271, 12687-90.
- Almasan, A. and Ashkenazi, A. Cytokine Growth Factor Rev 14, 337-48.
- Pan, G. et al. (1997) Science 276, 111-3.
- Walczak, H. et al. (1997) EMBO J 16, 5386-97.
- MacFarlane, M. et al. (1997) J Biol Chem 272, 25417-20.
- Chaudhary, P.M. et al. (1997) Immunity 7, 821-30.
- Schneider, P. et al. (1997) FEBS Lett 416, 329-34.
- Shetty, S. et al. (2002) Apoptosis 7, 413-20.
- Sheridan, J.P. et al. (1997) Science 277, 818-21.
- Degli-Esposti, M.A. et al. (1997) J Exp Med 186, 1165-70.
- Pan, G. et al. (1998) FEBS Lett 424, 41-5.
- Marsters, S.A. et al. (1997) Curr Biol 7, 1003-6.
- Kelley, S.K. et al. (2001) J Pharmacol Exp Ther 299, 31-8.
- Walczak, H. et al. (1999) Nat Med 5, 157-63.
- Ashkenazi, A. et al. (1999) J Clin Invest 104, 155-62.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
U.S. Patent No. 5,675,063.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
用户评论 --- 共 0 条